CONMED (US:CNMD) ZACKS·2025-05-01 00:05Core Viewpoint - Conmed (CNMD) reported a revenue of $321.26 million for the quarter ended March 2025, marking a year-over-year increase of 2.9% and exceeding the Zacks Consensus Estimate by 2.42% [1] Financial Performance - Earnings per share (EPS) for the quarter was $0.95, compared to $0.79 a year ago, resulting in an EPS surprise of 17.28% over the consensus estimate of $0.81 [1] - The stock has returned -13.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.2% change, and currently holds a Zacks Rank 3 (Hold) [3] Revenue Breakdown - Domestic revenue reached $183.80 million, surpassing the two-analyst average estimate of $175.66 million, with a year-over-year change of +4.2% [4] - International revenue was $137.50 million, slightly below the average estimate of $138.31 million, reflecting a year-over-year change of +1.2% [4] - Net sales in Orthopedic Surgery totaled $138.30 million, exceeding the average estimate of $125.60 million, with a year-over-year increase of +2.5% [4] - Net sales in General Surgery were $183 million, slightly above the average estimate of $182.04 million, showing a year-over-year change of +3.2% [4] - Net sales of Single-use Products amounted to $276.30 million, surpassing the average estimate of $268.71 million, with a year-over-year change of +4.4% [4] - Net sales of Capital Products were $45 million, slightly below the average estimate of $45.25 million, indicating a year-over-year decline of -5.5% [4]